HelpHelp About Us Contact Contact Us Help Help
Press Release Service
user name password
Client login:   
First time user sign up Forgot your login info?
Website Directory     Submit Website

Search
EmailWire News Links

Home > News By Company > Fuego Co.

Print e mail rss del Y! myWeb Tweet
 

Comprehensive Information On Therapeutic Development For Open-Angle Glaucoma, H1 2017

Comprehensive Information On Therapeutic Development For Open-Angle Glaucoma, H1 2017

 

Market Research Report




(EMAILWIRE.COM, January 06, 2017 ) Global Markets Directs, Open-Angle Glaucoma Pipeline Review, H1 2015, provides an overview of the Open-Angle Glaucomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=245117

Scope

The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=245117

Contact Information:
Fuego Co.
Researchmoz
Tel: +1-518-621-2074
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results


 

Search


Advertising | How to contact us | Privacy Statement | EmailWire Press Releases | Partnership Opportunities

EmailWire is a press release distribution service of GroupWeb Media LLC.

© Copyright GroupWeb Media LLC 2023